(MENAFN- GlobeNewsWire - Nasdaq) GAITHERSBURG, Md., Oct.10, 2019(GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences during the months of October and November:
| | H.C. Wainwright 3rd Annual NASH Investor Conference |
| | Date:
Time:
Speaker:
Location:
Webcast: | Monday, October 21
11:20am ET
M. Scott Harris M.D., Chief Medical Officer
St. Regis Hotel, New York City
https://ir.altimmune.com/investors/events-and-presentations
|
| | | |
| | BIO Investor Forum |
| | Date:
Time:
Speaker:
Location:
Webcast: | Wednesday, October 23
12:45pm ET/9:45am PT
Vipin K. Garg Ph. D., President and Chief Executive Officer
Westin St. Francis Hotel, San Francisco, CA
https://ir.altimmune.com/investors/events-and-presentations
|
| | | |
| | Jefferies 2019 London Healthcare Conference |
| | Date:
Attendees:
Location: | November 20 and November 21 (one-on-one meetings only)
Vipin K. Garg Ph.D., President and Chief Executive Officer
Will Brown, Chief Financial Officer
Waldorf Hilton, London, UK
|
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies. The Company's diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcellTM), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoShieldTM and NasoVAXTM). For more information on Altimmune, please visitwww.altimmune.com .
| Contacts | |
| Will Brown | Ashley R. Robinson |
| Chief Financial Officer | Managing Director LifeSci Advisors |
| Phone: 240-654-1450 | Phone: 617-535-7742 |
| Email: | Email: |
MENAFN1010201900703653ID1099108461
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.